[1]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973-976.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(7):973-976.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
点击复制

高血压合并糖尿病患者血压控制率和控制目标的探讨()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年7期
页码:
973-976
栏目:
综述
出版日期:
2019-10-25

文章信息/Info

Title:
Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes
作者:
黄秋瑾1 胡蓉2
1 胡蓉2(1. 重庆医科大学研究生院,重庆 400016 ;2. 重庆医科大学附属第二医院心血管内科,重庆 400016 )
Author(s):
HUANG Qiujin1HU Rong2
(1. Chongqing Medical University Graduate School, Chongqing 400016China2. Department of CardiologyThe Second Affiliated Hospital of Chongqing Medical UniversityChongqing 400016China)
关键词:
高血压糖尿病血压控制率血压控制目标
Keywords:
HypertensionDiabetesBlood pressure control rateBlood pressure control target
DOI:
10.16806/j.cnki.issn.1004-3934.2019.07.002
摘要:
高血压与糖尿病合并存在时将显著增加患者心脑血管事件及死亡风险。中囯高血压合并糖尿病患者的血压控制率明显低于发达国家,其中三级、二级医院的控制率高于一级医院,城市地区的控制率高于农村地区。国内外指南对高血压合并糖尿病患者的血压控制目标尚未达成共识,根据人群研究数据,推荐降压目标值为<130/80 mm Hg(1 mm Hg=0.133 3 kPa)。改善血压的控制率特别是初级卫生保健机构的控制情况,加强对高血压合并糖尿病的临床与基础研究,寻找更充分的循征医学证据是很有必要的。
Abstract:
The combination of hypertension and diabetes will significantly increase the risk of cardiovascular and cerebrovascular events and death in patients.The blood pressure control rate of patients with hypertension and diabetes in China is significantly lower than that of developed countries.The control rate of tertiary and secondary hospitals is higher than that of first-class hospitals,and the control rate of urban areas is higher than that of rural areas.Domestic and international guidelines have not reached a consensus on blood pressure control goals for patients with hypertension and diabetes.According to population data, the recommended target for blood pressure reduction is <130/80 mm Hg.Improving the control rate of blood pressure,especially the control of primary health care institutions,strengthening the clinical and basic research on hypertension and diabetes,it is necessary to find more evidence of medical evidence

参考文献/References:


[1] Stamler J,Vaccaro 0,Neaton JD,et al.Diabetes,other risk factors,and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Tria1[J].Diabetes Care,1993,l6(2):434-444.

[2] 刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93.

[3] Cooper-Dehoff RM,Pacanowski MA,Pepine CJ.Cardiovascular therapies and associated glucose homeostasis:implications across the dysglycemia continuum[J]. J Am Coll Cardiol, 2009,53(5 suppl):S28-S34.

[4] Balogun WO,Salako BL. Co-occurrence of diabetes and hypertension: Pattern and factors associated with order of diagnosis among Nigerians[J].Ann Ib Postgrad Med, 2011,9(2):89-93.

[5] Lastra G,Syed S,Kurukulasuriya LR,et al.Type 2 diabetes mellitus and hypertension:an update[J]. Endocrinol Metab Clin North Am, 2014, 43(1):103-122.

[6] 孙中明,潘恩春,缪丹丹,等.淮安市2型糖尿病合并高血压患者血压控制情况及其影响因素分析[J].中国慢性病预防与控制, 2017, 25(11):806-809.

[7] Adler AI. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study[J]. BMJ, 2000, 321(7258):412-419.

[8] ADVANCE Collaborative Group,Patel A,MacMahon S,et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med,2008,358(24):2560-2572.

[9] Ji L,Hu D,Pan C,et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients[J].Am J Med, 2013, 126(10):925.e11-e22.

[10] 孙宁玲,王鸿懿.我国高血压专病门诊患者血压控制及糖代谢调查现状分析[J]. 中华高血压杂志,2013,52(8):654-658.

[11] 林凡礼,战义强,贾贡献,等.中国门诊高血压患者血压达标现状及影响因素分析[J].中华高血压杂志, 2013(2):170-174.

[12] Suresh Kumar P, Sandhya AM. A study on the glycemic, lipid and blood pressure control of type 2 diabetes patients of Kerala[J]. Diabetes Metab Syndr, 2017,11(4):231-235.

[13] Grenier J,Goodman SG, Leiter LA, et al. Blood pressure?management?in adults with type 2?diabetes:?insights?from the?diabetes mellitus Status?in?Canada?(DM-SCAN)?survey[J]. Can JDiabetes,2018,42(2):130-137.

[14] Rehman H, Akeroyd JM, Ramsey D, et al. Facility-level variation in diabetes and blood pressure control in patients with diabetes: Findings from the Veterans Affairs national database[J]. Clin Cardiol, 2017,40(11):1055-1060.

[15] 秦明照,袁申元,傅汉菁,等.北京市15个社区2型糖尿病患者合并高血压率及血压达标的调查[J]. 中华全科医师杂志, 2013, 12(7):537-540.

[16] 杨群娣,阮晔,黎衍云,等.上海市社区管理2型糖尿病患者的血糖、血压及血脂控制情况分析[J].中国慢性病预防与控制,2015,23(8):561-564.

[17] Meneilly GS,Berard LD,Cheng AYY, et al. Insights into the current management of older adults with type 2 diabetes in the ontario primary care setting[J]. Can J Diabetes, 2018,42(1):23-30.

[18]Whelton PK,Carey RM,Aronow WS,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults[J]. J Am Coll Cardiol,2017,71(19):213-221.

[19] James PA,Oparil S,Carter BL,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the eighth Joint National Committee (JNC 8)[J].JAMA,2014,311(5): 507-520.

[20] 贾伟平,纪立农,翁建平,等.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018, 38(4):34-86.

[21] 王文.CSC 2016:中国高血压防治指南修订问题的解读[J].实用心脑肺血管病杂志, 2016,24(9):24-24.

[22] 罗富健,黄建凤.低舒张压与心血管疾病关系的研究进展[J].心血管病学进展, 2016,37(5):486-490.

[23] Xie X,Atkins E,Lv J. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis[J]. Lancet,?2016,387(10017):435-443.

[24] Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease:a systematic review and meta-analysis[J]. CMAJ,2013,185(11):949-957.

[25] Emdin CA,Rahimi K,Neal B, et al. Blood pressure lowering in type 2 diabetes:a systematic review and meta-analysis[J].JAMA,2015,313(6):603-615.

[26] Brunstr?m M,Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diab etes mellitus: systematic review and meta-analyses[J]. BMJ, 2016, 352: i717.

[27] Bangalore S,Toklu B,Gianos E,et al.Optimal systolic blood pressure target after SPRINT insights from a network meta-analysis of randomized trials[J].Am J Med, 2017,130(6):707-719.

[28] Bundy JD,Li C, Stuchlik P,et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality:a systematic review and network meta-analysis[J]. JAMA Cardiol, 2017,2(7):775-781.

[29] Wright JT,Williamson JD,Whelton PK,et al. A randomized trial of intensive versus standard blood-pressure control[J]. N Engl J Med, 2016, 42(8):e141-e143.

[30] ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes[J]. N Engl J Med,2010,362(17):1575-1585.

[31] Margolis KL,O’Connor PJ,Morgan TM,et al.Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes:the ACCORD randomized trial[J]. Diabetes Care, 2014, 37(6):1721-1728.

[32] Soliman EZ,Byington RP,Bigger JT,et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus[J]. Hypertension,2015,66(6):1123-1129.

[33] Buckley LF, Dixon DL, Wohlford GF, et al. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants[J].Diabetes Obes Metab,2018, 20(6):1499-1502.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
 SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(7):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]张若愚,综述,殷跃辉,等.2型糖尿病及其药物对心房颤动的影响[J].心血管病学进展,2016,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
 ZHANG Ruoyu,YIN Yuehui.Effect of Type 2 Diabetes Mellitus and Diabetic Drugs on Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(7):337.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.003]
[3]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
 FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(7):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[4]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
 CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(7):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[5]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
 ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[6]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
 ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(7):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
 ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
 LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(7):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
 WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(7):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]邹昕宇 杨帆 吴建军 邢磊.端粒长度在心脑血管疾病的研究进展[J].心血管病学进展,2022,(12):1131.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.017]
 ZOU Xinyu,YANG Fan,WU Jianjun,et al.Telomere Length in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(7):1131.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.017]
[12]张啸,刘剑刚,董国菊.射血分数保留性心力衰竭常见合并症的病理机制及治疗策略[J].心血管病学进展,2024,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]
 ZHANG Xiao,LIU Jiangang.The Pathophysiology and Treatment Strategies of Comorbidities in HFpEF[J].Advances in Cardiovascular Diseases,2024,(7):125.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]

更新日期/Last Update: 2019-12-16